Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cellectar Biosciences Inc CLRB

Healthcare Biotechnology
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CLRB)

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

GlobeNewswire 7 days ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

GlobeNewswire 11 days ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

GlobeNewswire 13 days ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

GlobeNewswire 13 days ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

GlobeNewswire November 7, 2024

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

GlobeNewswire November 1, 2024

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

GlobeNewswire August 26, 2024

Cellectar to Restate Previously Issued Financial Statements - Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

GlobeNewswire August 23, 2024

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

GlobeNewswire August 13, 2024
View More News ››

Opinion & Analysis (NDAQ:CLRB)

VIDEO: Cellectar Biosciences new technology to help treat cancer

BTV-Business Television November 5, 2014
View More Opinion ››

Bullboard Posts (NDAQ:CLRB)

Cellectar Biosciences Reports Financial Results for Q2 2024

BREAKING NEWS: $CLRB Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate UpdateFLORHAM PARK, N.J., Aug....
whytestocks - August 13, 2024

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endp

BREAKING NEWS: $CLRB Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal...
whytestocks - July 23, 2024

Cellectar Biosciences to Host Key Opinion Leader Event to Re

BREAKING NEWS: $CLRB Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial...
whytestocks - June 27, 2024

CLRB up in PM with Volume

Cellectar Biosciences (CLRB) Using its patented phospholipid drug conjugates (PDCs) delivery platform to specifically target cancer...
mattusvi - July 30, 2020

FDA Import Alert

For the record, the FDA Import Alert stopping CLR131 imports from CPDC can be found at  https://www.accessdata.fda.gov/cms_ia...
aee - January 21, 2019

Huge discrepancy in warrant pricing

I cannot believe that the warrants are trading at these prices CLRBZ $.66 CLRBW $.40 The CLRBZ warrants have an exercise price of $3...
RICHGUN - February 17, 2017
View more Bullboard ››

Mullen Group Ltd.

Mullen Group Ltd.

Mullen Group is one of North America's largest logistics providers with a network of independently operated businesses ...
View More »